Callidus Biopharma Inc. is developing a compound for Pompe's disease that links a therapeutic enzyme with a targeting peptide that could lead to more efficient delivery to diseased tissue and therefore require lower doses than marketed enzyme replacement therapies.

Callidus also believes its lead compound could be safer than a later-stage compound from BioMarin Pharmaceutical Inc. that uses a similar targeting peptide.